The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1510
December 19, 2016
View Complete Issue         Table of Contents 2019 
Celecoxib Safety Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Celecoxib Safety Revisited
December 19, 2016 (Issue: 1510)
The results of a clinical trial (PRECISION) comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib (Celebrex, and generics) with that of ibuprofen and naproxen, which are nonselective, have been described in the lay press in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Celecoxib Safety Revisited
Article code: 1510a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.